|
Name |
Ophiobolin P
|
| Molecular Formula | C25H36O4 | |
| IUPAC Name* |
(1S,3R,6R,7S,9E,13R,15R,16R)-13,15-dihydroxy-3,15-dimethyl-6-[(2S,3Z)-6-methylhepta-3,5-dien-2-yl]-12-oxatetracyclo[8.5.1.03,7.013,16]hexadec-9-en-11-one
|
|
| SMILES |
C[C@@H](/C=C\C=C(C)C)[C@H]1CC[C@]2([C@H]1C/C=C/3\[C@H]4[C@H](C2)[C@](C[C@]4(OC3=O)O)(C)O)C
|
|
| InChI |
InChI=1S/C25H36O4/c1-15(2)7-6-8-16(3)17-11-12-23(4)13-20-21-18(9-10-19(17)23)22(26)29-25(21,28)14-24(20,5)27/h6-9,16-17,19-21,27-28H,10-14H2,1-5H3/b8-6-,18-9+/t16-,17+,19-,20-,21-,23+,24+,25+/m0/s1
|
|
| InChIKey |
KNMOPFLBPXTWRO-UERVZAPGSA-N
|
|
| Synonyms |
CHEMBL4171012; Ophiobolin P; BDBM50523086
|
|
| CAS | NA | |
| PubChem CID | 73388106 | |
| ChEMBL ID | CHEMBL4171012 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 400.5 | ALogp: | 5.1 |
| HBD: | 2 | HBA: | 4 |
| Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 66.8 | Aromatic Rings: | 4 |
| Heavy Atoms: | 29 | QED Weighted: | 0.516 |
| Caco-2 Permeability: | -4.632 | MDCK Permeability: | 0.00001970 |
| Pgp-inhibitor: | 0.997 | Pgp-substrate: | 0.009 |
| Human Intestinal Absorption (HIA): | 0.179 | 20% Bioavailability (F20%): | 0.942 |
| 30% Bioavailability (F30%): | 0.939 |
| Blood-Brain-Barrier Penetration (BBB): | 0.062 | Plasma Protein Binding (PPB): | 97.11% |
| Volume Distribution (VD): | 1.973 | Fu: | 2.37% |
| CYP1A2-inhibitor: | 0.096 | CYP1A2-substrate: | 0.549 |
| CYP2C19-inhibitor: | 0.605 | CYP2C19-substrate: | 0.846 |
| CYP2C9-inhibitor: | 0.784 | CYP2C9-substrate: | 0.086 |
| CYP2D6-inhibitor: | 0.386 | CYP2D6-substrate: | 0.084 |
| CYP3A4-inhibitor: | 0.932 | CYP3A4-substrate: | 0.578 |
| Clearance (CL): | 9.425 | Half-life (T1/2): | 0.293 |
| hERG Blockers: | 0.312 | Human Hepatotoxicity (H-HT): | 0.626 |
| Drug-inuced Liver Injury (DILI): | 0.387 | AMES Toxicity: | 0.01 |
| Rat Oral Acute Toxicity: | 0.039 | Maximum Recommended Daily Dose: | 0.93 |
| Skin Sensitization: | 0.966 | Carcinogencity: | 0.07 |
| Eye Corrosion: | 0.026 | Eye Irritation: | 0.431 |
| Respiratory Toxicity: | 0.945 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003783 | ![]() |
0.632 | D0P0HT | ![]() |
0.269 | ||
| ENC002000 | ![]() |
0.632 | D0I2SD | ![]() |
0.267 | ||
| ENC005803 | ![]() |
0.530 | D04GJN | ![]() |
0.256 | ||
| ENC003251 | ![]() |
0.515 | D0L2LS | ![]() |
0.252 | ||
| ENC005047 | ![]() |
0.463 | D06AEO | ![]() |
0.250 | ||
| ENC003687 | ![]() |
0.459 | D0Q6NZ | ![]() |
0.250 | ||
| ENC002981 | ![]() |
0.389 | D04SFH | ![]() |
0.246 | ||
| ENC004491 | ![]() |
0.383 | D0B4RU | ![]() |
0.243 | ||
| ENC003209 | ![]() |
0.371 | D0K0EK | ![]() |
0.243 | ||
| ENC003777 | ![]() |
0.368 | D0KR5B | ![]() |
0.240 | ||